{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:04:03Z","timestamp":1746335043126},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s12253-019-00778-y","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T22:02:44Z","timestamp":1574719364000},"page":"1843-1850","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Relapse"],"prefix":"10.1007","volume":"26","author":[{"given":"Satoko","family":"Oka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Nohgawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"key":"778_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/annonc\/mdl327","volume":"18","author":"V Boehme","year":"2007","unstructured":"Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German high-grade non-Hodgkin's lymphoma study group (DSHNHL). Ann Oncol 18:149\u2013157","journal-title":"Ann Oncol"},{"key":"778_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1349-7006.2011.02139.x","volume":"103","author":"N Tomita","year":"2012","unstructured":"Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Yano T, Okamoto R, Kikuchi A, Tamura K, Sato K, Sunami K, Shibayama H, Takimoto R, Ohshima R, Hatta Y, Moriuchi Y, Kinoshita T, Yamamoto M, Numata A, Ishigatsubo Y, Takeuchi K (2012) Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 103:245\u2013251","journal-title":"Cancer Sci"},{"key":"778_CR3","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1007\/s12032-013-0520-0","volume":"30","author":"A Avil\u00e9s","year":"2013","unstructured":"Avil\u00e9s A, Jes\u00fas Nambo M, Neri N (2013) Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: an analysis of 3,258 patients in a single center. Med Oncol 30:520","journal-title":"Med Oncol"},{"key":"778_CR4","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.3109\/10428194.2011.596966","volume":"52","author":"D Chihara","year":"2011","unstructured":"Chihara D, Oki Y, Matsuo K, Onoda H, Taji H, Yamamoto K, Morishima Y (2011) Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leuk Lymphoma 52:2270\u20132275","journal-title":"Leuk Lymphoma"},{"key":"778_CR5","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00277-010-1150-7","volume":"90","author":"WM Tai","year":"2011","unstructured":"Tai WM, Chung J, Tang PL, Koo YX, Hou X, Tay KW, Quek R, Tao M, Lim ST (2011) Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol 90:809\u2013818","journal-title":"Ann Hematol"},{"key":"778_CR6","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","volume":"34","author":"N Schmitz","year":"2016","unstructured":"Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B, Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreundschuh M, Loeffler M, Savage KJ (2016) CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 34:3150\u20133156","journal-title":"J Clin Oncol"},{"key":"778_CR7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1182\/blood-2017-03-737460","volume":"130","author":"CK Chin","year":"2017","unstructured":"Chin CK, Cheah CY (2017) How I treat patients with aggressive lymphoma at high risk of CNS relapse. Blood. 130:867\u2013874","journal-title":"Blood."},{"key":"778_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/10245332.2016.1238183","volume":"22","author":"W Hu","year":"2017","unstructured":"Hu W, Wang X, Yang R, Bi L, Xie Y, Zhang Z, Lu H, Wu L (2017) Expression of CD56 is a risk factor for acute lymphocytic leukemia with central nervous system involvement in adults. Hematology. 22:81\u201387","journal-title":"Hematology."},{"key":"778_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/ajh.24299","volume":"91","author":"L Alinari","year":"2016","unstructured":"Alinari L, Gru A, Quinion C, Huang Y, Lozanski A, Lozanski G, Poston J, Venkataraman G, Oak E, Kreisel F, Park SI, Matthews S, Abramson JS, Iris Lim H, Martin P, Cohen JB, Evens A, al-Mansour Z, Singavi A, Fenske TS, Blum KA (2016) De novo CD5+ diffuse large B-cell lymphoma: adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. Am J Hematol 91:395\u2013399","journal-title":"Am J Hematol"},{"key":"778_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bjh.14770","volume":"179","author":"MJ Flynn","year":"2017","unstructured":"Flynn MJ, Hartley JA (2017) The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer. Br J Haematol 179:20\u201335","journal-title":"Br J Haematol"},{"key":"778_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0145-2126(94)90029-9","volume":"18","author":"K Nakase","year":"1994","unstructured":"Nakase K, Kita K, Anazawa H, Hoshino K, Shirakawa S, Tanaka I, Tsudo M (1994) Induction of interleukin-2 receptor alpha chain expression of immature acute myelocytic leukemia cells. Leuk Res 18:269\u2013274","journal-title":"Leuk Res"},{"key":"778_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ajh.2830460304","volume":"46","author":"K Nakase","year":"1994","unstructured":"Nakase K, Kita K, Nasu K, Ueda T, Tanaka I, Shirakawa S, Tsudo M (1994) Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms. Am J Hematol 46:179\u2013183","journal-title":"Am J Hematol"},{"key":"778_CR13","first-page":"1714","volume":"142","author":"H Tesch","year":"1993","unstructured":"Tesch H, G\u00fcnther A, Abts H et al (1993) Expression of interleukin-2R alpha and interleukin-2R beta in Hodgkin's disease. Am J Pathol 142:1714\u20131720","journal-title":"Am J Pathol"},{"key":"778_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10875-006-9060-0","volume":"27","author":"TA Waldmann","year":"2007","unstructured":"Waldmann TA (2007) Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol 27:1\u201318","journal-title":"J Clin Immunol"},{"issue":"3","key":"778_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3960\/jslrt.53.197","volume":"53","author":"Y Hashimoto","year":"2013","unstructured":"Hashimoto Y, Yokohama A, Saitoh A, Nakahashi H, Toyama K, Mitsui T, Koiso H, Saitoh T, Handa H, Uchiumi H, Jinbo T, Murayama K, Matsumoto M, Sawamura M, Karasawa M, Murakami H, Hirato J, Nojima Y, Kojima M, Tsukamoto N (2013) Prognostic importance of the soluble form of IL-2 receptor\u03b1 (sIL-2R\u03b1) and its relationship with surface expression of IL-2R\u03b1 (CD25) of lymphoma cells in diffuse large B-cell lymphoma treated with CHOP-like regimen with or without rituximab: a retrospective analysis of 338 cases. J Clin Exp Hematop 53(3):197\u2013205","journal-title":"J Clin Exp Hematop"},{"key":"778_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078730","volume":"8","author":"N Yoshida","year":"2013","unstructured":"Yoshida N, Oda M, Kuroda Y et al (2013) Clinical significance of sIL-2R levels in B-cell lymphomas. PLoS One 8:e78730","journal-title":"PLoS One"},{"key":"778_CR17","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1158\/2159-8290.CD-12-0208","volume":"2","author":"H Geng","year":"2012","unstructured":"Geng H, Brennan S, Milne TA et al (2012) Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov 2:1004\u20131023","journal-title":"Cancer Discov"},{"key":"778_CR18","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1182\/blood.V126.23.1434.1434","volume":"126","author":"JW Lee","year":"2015","unstructured":"Lee JW, Chen Z, Geng H et al (2015) CD25(IL2RA) orchestrates negative feedback control and stabilizes oncogenic signaling strength in acute lymphoblastic leukemia. Blood 126:1434","journal-title":"Blood"},{"key":"778_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1179\/1607845412Y.0000000024","volume":"18","author":"S Fujiwara","year":"2013","unstructured":"Fujiwara S, Muroi K, Hirata Y, Sato K, Matsuyama T, Ohmine K, Suzuki T, Ozaki K, Mori M, Nagai T, Tanaka A, Ozawa K (2013) Clinical features of de novo CD25(+) diffuse large B-cell lymphoma. Hematology. 18:14\u201319","journal-title":"Hematology."},{"key":"778_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3109\/10428194.2013.806658","volume":"55","author":"S Fujiwara","year":"2014","unstructured":"Fujiwara S, Muroi K, Tatara R, Matsuyama T, Ohmine K, Suzuki T, Mori M, Nagai T, Tanaka A, Ozawa K (2014) Clinical features of de novo CD25-positive follicular lymphoma. Leuk Lymphoma 55:307\u2013313","journal-title":"Leuk Lymphoma"},{"key":"778_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1182\/blood.V98.1.181","volume":"98","author":"S Ibrahim","year":"2001","unstructured":"Ibrahim S, Keating M, Do KA et al (2001) CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 98:181\u2013186","journal-title":"Blood."},{"key":"778_CR22","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(12)60626-6","volume":"379","author":"T Tanimoto","year":"2012","unstructured":"Tanimoto T, Kusumi E, Hosoda K et al (2012) CNS prophylaxis in diffuse large B-cell lymphoma. Lancet. 379:1485\u20131486","journal-title":"Lancet."},{"key":"778_CR23","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bjh.12982","volume":"166","author":"Y Oki","year":"2014","unstructured":"Oki Y, Noorani M, Lin P et al (2014) Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166:891\u2013901","journal-title":"Br J Haematol"},{"key":"778_CR24","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","volume":"124","author":"AM Petrich","year":"2014","unstructured":"Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens AM, Shah N, Fenske TS, Zelenetz AD, Landsburg DJ, Howlett C, Mato A, Jaglal M, Chavez JC, Tsai JP, Reddy N, Li S, Handler C, Flowers CR, Cohen JB, Blum KA, Song K, Sun HL, Press O, Cassaday R, Jaso J, Medeiros LJ, Sohani AR, Abramson JS (2014) Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 124:2354\u20132361","journal-title":"Blood."},{"key":"778_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/annonc\/mdh013","volume":"15","author":"P Feugier","year":"2004","unstructured":"Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, Bordessoule D, Recher C, Blanc M, Molina T, Lederlin P, Coiffier B (2004) Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 15:129\u2013133","journal-title":"Ann Oncol"},{"key":"778_CR26","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1093\/annonc\/mdp432","volume":"21","author":"D Villa","year":"2010","unstructured":"Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ (2010) Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 21:1046\u20131052","journal-title":"Ann Oncol"},{"key":"778_CR27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1600-0609.2010.01438.x","volume":"85","author":"W Yamamoto","year":"2010","unstructured":"Yamamoto W, Tomita N, Watanabe R, Hattori Y, Nakajima Y, Hyo R, Hashimoto C, Motomura S, Ishigatsubo Y (2010) Central nervous system involvement in diffuse large B-cell lymphoma. Eur J Haematol 85:6\u201310","journal-title":"Eur J Haematol"},{"key":"778_CR28","first-page":"259","volume":"26","author":"N Shahab","year":"1999","unstructured":"Shahab N, Doll DC (1999) Testicular lymphoma. Semin Oncol 26:259\u2013269","journal-title":"Semin Oncol"},{"key":"778_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/JCO.2003.11.141","volume":"21","author":"E Zucca","year":"2003","unstructured":"Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, Klasa R, Ozsahin M, Mead GM, Gianni MA, Cortelazzo S, Ferreri AJ, Ambrosetti A, Martelli M, Thi\u00e9blemont C, Moreno HG, Pinotti G, Martinelli G, Mozzana R, Grisanti S, Provencio M, Balzarotti M, Laveder F, Oltean G, Callea V, Roy P, Cavalli F, Gospodarowicz MK, International Extranodal Lymphoma Study Group (2003) Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the international Extranodal lymphoma study group. J Clin Oncol 21:20\u201327","journal-title":"J Clin Oncol"},{"key":"778_CR30","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1080\/1042819021000006475","volume":"43","author":"SL Chua","year":"2002","unstructured":"Chua SL, Seymour JF, Streater J, Wolf MM, Januszewicz EH, Prince HM (2002) Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 43:1783\u20131788","journal-title":"Leuk Lymphoma"},{"key":"778_CR31","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1002\/cncr.26588","volume":"118","author":"A Kumar","year":"2012","unstructured":"Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA (2012) Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 118:2944\u20132951","journal-title":"Cancer."},{"key":"778_CR32","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/blood.V128.22.1855.1855","volume":"128","author":"EH Phillips","year":"2016","unstructured":"Phillips EH, Kirkwood AA, Lawrie A et al (2016) Low rates of CNS relapse in high risk DLBCL patients treated with R-CODOX-M and R-IVAC: results from a phase 2UK NCRI\/Bloodwise trial. Blood 128:1855","journal-title":"Blood"},{"key":"778_CR33","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","volume":"133","author":"C Grommes","year":"2019","unstructured":"Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, Piotrowski AF, Stone J, Lin A, Nolan CP, Manne M, Codega P, Campos C, Viale A, Thomas AA, Berger MF, Hatzoglou V, Reiner AS, Panageas KS, DeAngelis L, Mellinghoff IK (2019) Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma. Blood. 133:436\u2013445","journal-title":"Blood."},{"key":"778_CR34","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","volume":"2","author":"JL Rubenstein","year":"2018","unstructured":"Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J, Killea P, Choi K, Ventura J, Kurhanewicz J, Lowell C, Hwang J, Treseler P, Sneed PK, Li J, Wang X, Chen N, Gangoiti J, Munster PN, Damato B (2018) Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595\u20131607","journal-title":"Blood Adv"}],"container-title":["Pathology & Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-019-00778-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-019-00778-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-019-00778-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T18:26:56Z","timestamp":1722104816000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-019-00778-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["778"],"URL":"https:\/\/doi.org\/10.1007\/s12253-019-00778-y","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"value":"1219-4956","type":"print"},{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,25]]},"assertion":[{"value":"16 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Satoko Oka declares that she has no conflicts of interest in the present study.Kazuo Ono declares that he has no conflicts of interest in the present study.Masaharu Nohgawa declares that he has no conflicts of interest in the present study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Studies"}},{"value":"These patients provided their written informed consent to receive each regimens, and treatments were administered according to the principles of the Declaration of Helsinki and this study was approved by the institutional ethics committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}